Arecor Therapeutics (AREC) H1 2024 earnings summary

Executive summary

• Focused on transforming patient care with enhanced therapeutic medicines using proprietary Arestat technology, targeting high-value diabetes and obesity markets.

• Diverse, de-risked portfolio includes in-house products and revenue-generating partnerships with major pharma and med tech companies.

• Recent clinical data for AT278, a highly concentrated, ultra-rapid insulin, shows superior performance, supporting strategic discussions with device companies.

• Ogluo, a ready-to-use glucagon pen, is being actively marketed in the UK and Germany, with growth strategies in place.

Financial highlights

• Revenue increased by 20% compared to the first half of 2023.

• Slight reduction in R&D investment due to timing and completion of clinical studies.

• Recurring royalties from AT220, now available in the EU and US, contribute to revenue.

• Cash at end of June was £2.5 million, prior to a £6.4 million fundraise.

Outlook and guidance

• Anticipates a strong second half of 2024 with increasing revenues across a diversified portfolio.

• Focused R&D investment in diabetes and oral peptide delivery, especially GLP-1 programs.

• Ongoing strategic and co-development discussions for AT278 with device companies.

• Pipeline of new licensing and technology partnership opportunities expected to yield new deals in 2024 and 2025.

• Planned headcount reduction to manage cash and achieve annualized savings.